Followers | 186 |
Posts | 10754 |
Boards Moderated | 4 |
Alias Born | 06/20/2022 |
![](https://investorshub.advfn.com/uicon/824868.png?cb=1718637286)
Thursday, October 06, 2022 10:40:31 AM
Recent SNTI News
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 05/29/2024 08:14:07 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/29/2024 08:09:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 05/29/2024 08:07:46 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/17/2024 09:19:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 09:17:02 PM
- Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia • GlobeNewswire Inc. • 05/13/2024 12:15:53 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:15:14 PM
- Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights • GlobeNewswire Inc. • 05/09/2024 08:05:33 PM
- Senti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML) • GlobeNewswire Inc. • 04/30/2024 12:05:36 PM
- Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights • GlobeNewswire Inc. • 03/21/2024 08:05:49 PM
- Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program • GlobeNewswire Inc. • 01/05/2024 09:05:00 PM
- Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia • GlobeNewswire Inc. • 12/22/2023 11:30:00 AM
- Senti Bio Announces Third Quarter 2023 Results and Pipeline Updates • GlobeNewswire Inc. • 11/13/2023 09:15:00 PM
- Senti Bio Announces New Strategic Collaboration with Celest Therapeutics for Clinical Development of SENTI-301A in China • GlobeNewswire Inc. • 11/06/2023 09:05:00 PM
- Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer Annual Meeting • GlobeNewswire Inc. • 10/31/2023 01:06:00 PM
- Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer 2023 Meeting • GlobeNewswire Inc. • 09/27/2023 01:05:00 PM
- Senti Bio to Participate in Upcoming Conferences • GlobeNewswire Inc. • 09/26/2023 08:05:00 PM
- Senti Bio to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 09/05/2023 12:30:00 PM
- Senti Bio Announces Second Quarter 2023 Results and Pipeline Updates • GlobeNewswire Inc. • 08/11/2023 12:35:00 PM
- Senti Bio Announces Closing of Transaction Leveraging its CMC Capabilities into a Cell and Gene Therapy Manufacturing Innovation Business Backed by Celadon Partners • GlobeNewswire Inc. • 08/10/2023 12:35:00 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM